16th July 2012 - News release


The role of UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinsonís disease and moderate-to-severe primary Restless Legs Syndrome. Neupro is a once-daily patch that provides continuous delivery of the dopamine agonist rotigotine for 24 hours. Neupro is available in four different dosage strengths for the signs and symptoms of Parkinsonís disease (2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours, and 8 mg/24 hours).

In clinical trials, the most common adverse reactions were nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, insomnia, hyperhidrosis, peripheral edema, and dyskinesia. There is an increased risk for hallucinations in people with advanced-stage Parkinsonís Disease when they are treated with Neupro. Neupro may cause symptomatic postural/orthostatic hypotension and syncope (fainting), especially during dose escalation, elevated blood pressure, elevated heart rate, weight gain and fluid retention. Neupro should be used with caution in people with severe cardiovascular disease.

Case reports suggest that patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and other intense urges, and the inability to control these urges while taking medications including Neupro. For more information, go to the News release. For a printable version of this article click here For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports


©2006-2013  Viartis
2015-09-03 13:15:35
[email protected]